Another theory I just read was NRXP doesn't want to offend BP by calling out the poor showing of Remdesivir (yet) in the PR. Rather leave the 'devil in the details' inside the EUA Application submitted to the FDA to first get the EUA. Then after EUA is granted, then pull out the stops in slamming Remdesivir.
Market Data 
Markets 
AI
